...and improves oxygen therapy.

Get full access to Reuters.com for just $1/week. Subscribe now.

 

Health Rounds

Health Rounds

By Nancy Lapid, Health Science Editor

Hello Health Rounds readers! Today we report on two more ways in which artificial intelligence can be used to enhance medical care, one as a prognostic tool and the other to maintain proper oxygen levels, potentially in a battlefield setting. We also report on another promising experimental non-opioid pain drug for use following surgery. 

In breaking U.S. news, the largest known cyclosporiasis outbreak expands to 15 states while cases in Michigan climb to 11,508 and officials there report the outbreak’s first deaths; FAA proposes giving airlines flexibility on flight emergency medical kits; Democrats see universal health care, taxing the rich as 'essential'; a single US measles outbreak can cost millions of dollars; and the Trump administration is sued over its ban on trans care coverage for federal workers.

And outside the U.S., Afghan child malnutrition surges as aid cuts force clinics to turn families away; treatment trials for Ebola strain behind Congo outbreak show promise; months after Pemex gas well accident in Mexico, health and pollution concerns grow; Australia defends teen social media ban after study shows most still online; and Romanian healthcare workers end strike over pay, staffing.

 

Industry Updates

  • Quarterly reports and earnings forecasts from Amgen; Gilead; Novo; BioNTech; Pfizer; Merck; Convatec; Vertex; GSK India; Moderna; AbbVie; and Siemens Healthineers.
  • Medtronic owes $88 million after trial over hernia mesh.
  • P&G buys supplements maker Thorne for $3.8 billion.
  • Eli Lilly to offer early access to next-gen obesity drug.
  • Curium makes up to $8 billion deal for Lantheus.
  • Supernus, Indivior merge to strengthen neuroscience drug portfolio.
  • AstraZeneca investors balk at $400 billion Bristol Myers deal.
  • Sandoz agrees to $450 mln settlement with 43 US states.
  • Novo claws way back into obesity race with Lilly.
  • Amgen discloses patient data breach.
  • Replimune surges after FDA advisers back skin cancer drug.
 
 

Moderna begins first human trial of Bundibugyo Ebola vaccine

REUTERS/Dado Ruvic/Illustration/File Photo

Moderna has begun to test in Canadian volunteers what could become the first vaccine against the Bundibugyo strain of Ebola that has killed more than 1,650 ‌people so far. Read more here.

 

Study Rounds

AI helps find untapped health predictors in sleep studies

 

Analyzing routine sleep study data with artificial intelligence reveals a wealth of biomarkers predictive of a much broader range of health risks than doctors usually identify, researchers have found.

Polysomnograms, or in-lab sleep studies, are typically performed to look for obstructive sleep apnea, a common disorder in which throat muscles relax and repeatedly block the airway during sleep.

The studies collect data on breathing, brain and muscle activity and other factors, but doctors generally focus on the apnea-hypopnea index, or the average number of breathing pauses and shallow breathing events per hour.

For the new study, investigators tasked AI with uncovering hidden physiologic patterns in more than 10,000 full-night sleep studies and linking the patterns with long-term clinical outcomes in patients’ medical records.

AI, using a wealth of data typically ignored during such studies, identified five clinically meaningful patient subtypes, each with sharply different long-term health risks, they reported in Nature.

For example, patients whose sleep data patterns put them in the highest-risk group for serious health issues had twice the odds of death over the next five years compared to those in the lowest-risk group, a distinction not captured by the apnea-hypopnea index.

In this most at-risk group, odds were 65% higher for heart failure, 84% higher for heart attack, 93% higher for cognitive impairment, and more than 200% higher for atrial fibrillation and for epilepsy, compared to odds in the lowest-risk group.

AI predicted outcomes well for men and women, while the apnea-hypopnea index has historically performed better in men, the researchers noted.

Their model was equally accurate when they tested it in a separate nationwide cohort of more than 6,000 patients, they said.

“For decades we have distilled an overnight sleep study into a handful of summary measures,” study leader Dr. Reena Mehra of the University of Washington said in a statement.

“AI gives us the opportunity to move beyond those summaries and learn from the full richness of sleep physiology.”

 

Read more about AI in medicine on Reuters.com

  • AI shortens drug discovery to around 1 year in China, Insilico CEO says
  • OpenAI launches AI model GPT-Rosalind for life sciences research
  • US insurers and hospitals turn to new AI for age-old battle over charges vs payments